<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03158272</url>
  </required_header>
  <id_info>
    <org_study_id>CA025-001</org_study_id>
    <nct_id>NCT03158272</nct_id>
  </id_info>
  <brief_title>A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread</brief_title>
  <official_title>A Phase 1 Study of Cabiralizumab (BMS-986227, FPA008) Administered Alone or in Combination With Nivolumab (BMS-936558) in Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether an investigational immuno-therapy,
      cabiralizumab in combination with nivolumab, is safe and tolerable in the treatment of
      advanced malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2017</start_date>
  <completion_date type="Actual">October 24, 2019</completion_date>
  <primary_completion_date type="Actual">October 23, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel assignment will only in combination therapy arm.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidenence of Adverse Events (AEs)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety and tolerability of cabiralizumab as monotherapy in subjects with advanced solid tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety and tolerability of cabiralizumab as monotherapy in subjects with advanced solid tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety and tolerability of cabiralizumab as monotherapy in subjects with advanced solid tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of death</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety and tolerability of cabiralizumab as monotherapy in subjects with advanced solid tumors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety of cabiralizumab in combination with nivolumab in subjects with advanced solid tumors and hematologic malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety of cabiralizumab in combination with nivolumab in subjects with advanced solid tumors and hematologic malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety of cabiralizumab in combination with nivolumab in subjects with advanced solid tumors and hematologic malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed concentration (Ctrough) Accumulation Index; ratio of Ctrough at steady-state (AI_Ctrough)</measure>
    <time_frame>Up to one year</time_frame>
    <description>Summary measures of pharmacokinetic (PK) parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to [AUC(0-T)</measure>
    <time_frame>Up to one year</time_frame>
    <description>Summary measures of PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>Up to one year</time_frame>
    <description>Summary measures of PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Ctrough)</measure>
    <time_frame>Up to one year</time_frame>
    <description>Summary of PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life that explains the degree of Ctrough (T-HALFeff_Ctrough)</measure>
    <time_frame>Up to one year</time_frame>
    <description>Summary measures of PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax)</measure>
    <time_frame>Up to one year</time_frame>
    <description>Summary measures of PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss)</measure>
    <time_frame>Up to one year</time_frame>
    <description>Summary measures of PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Antidrug Antibodies (ADA)</measure>
    <time_frame>Up to four years</time_frame>
    <description>To characterize the immunogenicity of cabiralizumab and nivolumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>Up to two years</time_frame>
    <description>Assessed per RECIST 1.1 or International Myeloma Working Group (IMWG) Response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to two years</time_frame>
    <description>Assessed per RECIST 1.1 or IMWG Response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of death</measure>
    <time_frame>Up to two years</time_frame>
    <description>To assess the safety of cabiralizumab in combination with nivolumab in subjects with advanced solid tumors and hematologic malignancies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabiralizumab administered as a single agent intravenous formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabiralizumab will be administered in combination with Nivolumab as an intravenous formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cabiralizumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Combination Therapy</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Performance status 0-1

          -  Adequate organ function

          -  Cohort M1, 2 and C1: Measurable disease

          -  Cohort M1, M2 and C1: Subjects must have histologic or cytologic confirmation of an
             advanced (metastatic and/or unresectable) malignant solid tumor

          -  Cohort C2: Documented refractory or relapsed multiple myeloma

          -  Subjects must be refractory to or have relapsed after standard therapies, or have no
             known effective treatment

        Exclusion Criteria:

          -  Cohort M1, M2, and C1: Untreated or active central nervous system (CNS) or
             leptomeningeal metastases

          -  Cohort M1, M2, and C1: Subjects with hepatocellular carcinoma (HCC)

          -  Cohort C2: Subjects with solitary bone or extramedullary plasmacytoma as the only
             evidence of plasma cell dyscrasia

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>4678602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kamogawa-shi</city>
        <state>Chiba</state>
        <zip>2968602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>2778577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>1040045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 16, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

